These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 22686944)

  • 21. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.
    Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Fogari E; Bertone G; Ciccarelli L; Piccinni MN
    Clin Ther; 2004 May; 26(5):744-54. PubMed ID: 15220018
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of therapy with metformin plus pioglitazone in the treatment of patients with type 2 diabetes: a double-blind, placebo-controlled, clinical trial.
    Kaku K
    Curr Med Res Opin; 2009 May; 25(5):1111-9. PubMed ID: 19309251
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension.
    Kadowaki T; Kondo K
    Diabetes Obes Metab; 2014 May; 16(5):418-25. PubMed ID: 24205974
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study.
    Bosi E; Ellis GC; Wilson CA; Fleck PR
    Diabetes Obes Metab; 2011 Dec; 13(12):1088-96. PubMed ID: 21733058
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy.
    Berhanu P; Perez A; Yu S
    Diabetes Obes Metab; 2007 Jul; 9(4):512-20. PubMed ID: 17587394
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5.
    Home PD; Shamanna P; Stewart M; Yang F; Miller M; Perry C; Carr MC
    Diabetes Obes Metab; 2015 Feb; 17(2):179-87. PubMed ID: 25406730
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pioglitazone is effective therapy for elderly patients with type 2 diabetes mellitus.
    Rajagopalan R; Perez A; Ye Z; Khan M; Murray FT
    Drugs Aging; 2004; 21(4):259-71. PubMed ID: 15012171
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P).
    Pinget M; Goldenberg R; Niemoeller E; Muehlen-Bartmer I; Guo H; Aronson R
    Diabetes Obes Metab; 2013 Nov; 15(11):1000-7. PubMed ID: 23627775
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.
    Aronoff S; Rosenblatt S; Braithwaite S; Egan JW; Mathisen AL; Schneider RL
    Diabetes Care; 2000 Nov; 23(11):1605-11. PubMed ID: 11092281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus.
    Kothny W; Foley J; Kozlovski P; Shao Q; Gallwitz B; Lukashevich V
    Diabetes Obes Metab; 2013 Mar; 15(3):252-7. PubMed ID: 23039321
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin.
    Reusch J; Stewart MW; Perkins CM; Cirkel DT; Ye J; Perry CR; Reinhardt RR; Bode BW
    Diabetes Obes Metab; 2014 Dec; 16(12):1257-64. PubMed ID: 25155146
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of linagliptin on glycaemic control and tolerability in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
    Singh-Franco D; McLaughlin-Middlekauff J; Elrod S; Harrington C
    Diabetes Obes Metab; 2012 Aug; 14(8):694-708. PubMed ID: 22340363
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy.
    Rosenstock J; Vico M; Wei L; Salsali A; List JF
    Diabetes Care; 2012 Jul; 35(7):1473-8. PubMed ID: 22446170
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy.
    Henriksen K; Byrjalsen I; Qvist P; Beck-Nielsen H; Hansen G; Riis BJ; Perrild H; Svendsen OL; Gram J; Karsdal MA; Christiansen C;
    Diabetes Metab Res Rev; 2011 May; 27(4):392-401. PubMed ID: 21328517
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study.
    Seino Y; Miyata Y; Hiroi S; Hirayama M; Kaku K
    Diabetes Obes Metab; 2012 Oct; 14(10):927-36. PubMed ID: 22583697
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents.
    Derosa G
    Drugs; 2010 Oct; 70(15):1945-61. PubMed ID: 20883052
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus.
    Kovacs CS; Seshiah V; Merker L; Christiansen AV; Roux F; Salsali A; Kim G; Stella P; Woerle HJ; Broedl UC;
    Clin Ther; 2015 Aug; 37(8):1773-88.e1. PubMed ID: 26138864
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of alogliptin in patients with type 2 diabetes mellitus: A multicentre randomized double-blind placebo-controlled Phase 3 study in mainland China, Taiwan, and Hong Kong.
    Pan C; Han P; Ji Q; Li C; Lu J; Yang J; Li W; Zeng J; Hsieh AT; Chan J
    J Diabetes; 2017 Apr; 9(4):386-395. PubMed ID: 27171508
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Can a selective PPARγ modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone?
    DePaoli AM; Higgins LS; Henry RR; Mantzoros C; Dunn FL;
    Diabetes Care; 2014 Jul; 37(7):1918-23. PubMed ID: 24722496
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of colesevelam in combination with pioglitazone in patients with type 2 diabetes mellitus.
    Rosenstock J; Truitt KE; Baz-Hecht M; Ford DM; Tao B; Chou HS
    Horm Metab Res; 2014 Dec; 46(13):943-9. PubMed ID: 25054436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.